Form 4: Sonnet BioTherapeutics Interim CEO Granted 20,000 Restricted Stock Units

Sonnet BioTherapeutics Holdings, Inc. has granted its Interim CEO, Raghu Rao, 20,000 restricted stock units, which will vest fully by January 8, 2026, or upon a change in control.

Summary

• Raghu Rao, Interim CEO and Director of Sonnet BioTherapeutics Holdings, Inc. (SONN), was granted 20,000 restricted stock units (RSUs) on July 11, 2025.
• These RSUs will be settled in shares of common stock, par value $0.0001.
• The RSUs vest 100% on the earlier of January 8, 2026, or the date of a 'Change in Control' as defined under the Issuer's 2020 Omnibus Equity Incentive Plan.
• Following this transaction, Raghu Rao beneficially owns 22,356 shares, which includes these unvested restricted stock units.
• All reported amounts reflect the company's 1:22 reverse stock split effective August 31, 2023, and a subsequent 1:8 reverse stock split effective September 30, 2024.

Sentiment

Score: 6

Explanation: The grant of RSUs to an executive is generally a neutral to slightly positive event, indicating alignment of interests. However, the historical context of multiple reverse stock splits suggests past challenges, which tempers overall sentiment.

Positives

• The grant of restricted stock units to the Interim CEO aligns management's interests with shareholder value, as the value of the grant is tied to the company's stock performance.
• The vesting schedule provides an incentive for continued leadership and stability through at least early 2026.

Negatives

• The company has undergone two significant reverse stock splits (1:22 on August 31, 2023, and 1:8 on September 30, 2024), which often indicate a history of significant stock price decline or dilution and can be viewed negatively by investors.

Risks

• The vesting of the restricted stock units can be accelerated upon a 'Change in Control,' which could lead to immediate dilution if a change in control event occurs.

Future Outlook

The restricted stock units granted to the Interim CEO are set to vest fully by January 8, 2026, or earlier upon a change in control, indicating a future milestone for executive compensation.

Management Changes

Stakeholder Impact

• Shareholders: The grant of RSUs to the Interim CEO aligns his interests with shareholder value, as the value of his compensation is tied to the company's stock performance. However, it also represents potential future dilution upon vesting.
• Employees: The grant is specific to the Interim CEO and does not directly impact other employees, though it sets a precedent for executive compensation.

Next Steps

• The restricted stock units will vest on the earlier of January 8, 2026, or a 'Change in Control' event.

Key Dates

Keywords

Sonnet BioTherapeutics, SONN, Raghu Rao, Restricted Stock Units, RSU grant, SEC Form 4, Beneficial Ownership, Executive Compensation, Reverse Stock Split, Corporate Governance